Abstract
Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
CNS & Neurological Disorders - Drug Targets
Title:Conference Report
Volume: 11 Issue: 3
Author(s): Stephen D. Skaper
Affiliation:
Abstract: Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
Export Options
About this article
Cite this article as:
D. Skaper Stephen, Conference Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672427
DOI https://dx.doi.org/10.2174/187152712800672427 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Current Molecular Pharmacology Subject Index To Volume 13
Current Medicinal Chemistry MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Human Microdialysis
Current Pharmaceutical Biotechnology Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Cerebral Microemboli Increase β-amyloid Protein Deposition, MMP-9, and GFAP Expression in the Alzheimer`s Model of APP/PS1 Double Transgenic Mice
Current Neurovascular Research The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Current Issues in Intravenous Fluid Use in Hospitalized Children
Reviews on Recent Clinical Trials Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Traumatic Brain Injury: A Forensic Approach: A Literature Review
Current Neuropharmacology Editorial (Thematic Issue: Targeting Phosphodiesterases (PDEs) for Treatment of CNS Diseases)
Current Pharmaceutical Design